DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer
Purpose: The aim of this study was to evaluate the utility of the DNA integrity assay (DIA) as a plasma-based screening tool for the detection of prostate cancer. Experimental Design: Blood samples were collected from patients with biopsy-proven prostate cancer prior to prostatectomy ( n = 123) and...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-08, Vol.12 (15), p.4569-4574 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4574 |
|---|---|
| container_issue | 15 |
| container_start_page | 4569 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | HANLEY, Robert RIEGER-CHRIST, Kimberly M CANES, David EMARA, Norah R SHUBER, Anthony P BOYNTON, Kevin A LIBERTINO, John A SUMMERHAYES, Ian C |
| description | Purpose: The aim of this study was to evaluate the utility of the DNA integrity assay (DIA) as a plasma-based screening tool for the
detection of prostate cancer.
Experimental Design: Blood samples were collected from patients with biopsy-proven prostate cancer prior to prostatectomy ( n = 123) and processed as two-spin plasma preparations. The three control groups included: males |
| doi_str_mv | 10.1158/1078-0432.CCR-06-0130 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68729958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68729958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-dfc7efbcdfb5960b467c1bab2d78043fce8c6cb3582f0e7d65628cf54b39d30d3</originalsourceid><addsrcrecordid>eNqFkElP6zAURi30EPNPeE_ePCQWAQ-x47ArYZQQIAaxtBznug1Kk2K7Qv33uLSIJat7F-e7w0HoLyXHlAp1QkmhMpJzdlxVjxmRGaGcbKAdKkSRcSbFn9R_M9toN4Q3QmhOSb6FtqlUZSkJ30Gv53cjfNNHGPs2LvAoBLM4xSP80JkwNdmZCdDgJ-sB-rYf4-dh6LAbPI4TwOcQwcZ26PHg8IMfQjQRcGV6C34fbTrTBThY1z30cnnxXF1nt_dXN9XoNrOCipg1zhbgatu4WqSD6lwWltamZk2h0uHOgrLS1lwo5ggUjRSSKetEXvOy4aThe-hwNXfmh_c5hKinbbDQdaaHYR60VAUrS6F-BVnyl3MhEyhWoE0fBQ9Oz3w7NX6hKdFL9XqpVS-16qReE6mX6lPu33rBvJ5C85Nau07A_zVggjWd80lUG344RThjqkjc0YqbtOPJR-tB2y-lHgIYbyeaMk2FzoUs-SeMtJnF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20134356</pqid></control><display><type>article</type><title>DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>HANLEY, Robert ; RIEGER-CHRIST, Kimberly M ; CANES, David ; EMARA, Norah R ; SHUBER, Anthony P ; BOYNTON, Kevin A ; LIBERTINO, John A ; SUMMERHAYES, Ian C</creator><creatorcontrib>HANLEY, Robert ; RIEGER-CHRIST, Kimberly M ; CANES, David ; EMARA, Norah R ; SHUBER, Anthony P ; BOYNTON, Kevin A ; LIBERTINO, John A ; SUMMERHAYES, Ian C</creatorcontrib><description>Purpose: The aim of this study was to evaluate the utility of the DNA integrity assay (DIA) as a plasma-based screening tool for the
detection of prostate cancer.
Experimental Design: Blood samples were collected from patients with biopsy-proven prostate cancer prior to prostatectomy ( n = 123) and processed as two-spin plasma preparations. The three control groups included: males <40 years old with no history
of cancer (group 1, n = 20); cancer-free postprostatectomy patients (group 2, n = 25), and patients with a negative prostate biopsy (group 3, n = 22). DNA in plasma preparations were isolated, hybrid-captured, and DNA fragments (200 bp, 1.3, 1.8, and 2.4 kb) were multiplexed
in real-time PCR. A baseline cutoff was determined for individual fragment lengths to establish a DIA score for each patient
sample.
Results: Patients with prostate cancer (86 of 123; 69.9%) were determined to have a positive DIA score of ≥7. The DIA results from
control groups 1, 2, and 3 showed specificities of 90%, 92%, and 68.2%, respectively. Of the patients with negative age-adjusted
prostate-specific antigen (PSA) and prostate cancer, 19 of 30 (63%) had a positive DIA score. The area under the receiver
operating characteristic curve for DIA was 0.788.
Conclusion: While detecting 69.9% of those with prostate cancer, DIA maintained an overall specificity of 68.2% to 92%, a range favorably
comparable to that currently accepted for PSA (60-70%). The variability in specificity between control groups is likely explained
by the established 19% to 30% detection of prostate cancer on subsequent biopsies associated with control group 3. DIA detected
63% of the prostate cancers undetected by currently accepted PSA ranges.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-06-0130</identifier><identifier>PMID: 16899603</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Antineoplastic agents ; Biological and medical sciences ; cell-free DNA ; DNA integrity assay (DIA) ; DNA, Neoplasm - blood ; DNA, Neoplasm - genetics ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Pharmacology. Drug treatments ; plasma, prostate cancer ; Predictive Value of Tests ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Reverse Transcriptase Polymerase Chain Reaction - methods ; Sensitivity and Specificity ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Clinical cancer research, 2006-08, Vol.12 (15), p.4569-4574</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-dfc7efbcdfb5960b467c1bab2d78043fce8c6cb3582f0e7d65628cf54b39d30d3</citedby><cites>FETCH-LOGICAL-c515t-dfc7efbcdfb5960b467c1bab2d78043fce8c6cb3582f0e7d65628cf54b39d30d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3354,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18032287$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16899603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HANLEY, Robert</creatorcontrib><creatorcontrib>RIEGER-CHRIST, Kimberly M</creatorcontrib><creatorcontrib>CANES, David</creatorcontrib><creatorcontrib>EMARA, Norah R</creatorcontrib><creatorcontrib>SHUBER, Anthony P</creatorcontrib><creatorcontrib>BOYNTON, Kevin A</creatorcontrib><creatorcontrib>LIBERTINO, John A</creatorcontrib><creatorcontrib>SUMMERHAYES, Ian C</creatorcontrib><title>DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: The aim of this study was to evaluate the utility of the DNA integrity assay (DIA) as a plasma-based screening tool for the
detection of prostate cancer.
Experimental Design: Blood samples were collected from patients with biopsy-proven prostate cancer prior to prostatectomy ( n = 123) and processed as two-spin plasma preparations. The three control groups included: males <40 years old with no history
of cancer (group 1, n = 20); cancer-free postprostatectomy patients (group 2, n = 25), and patients with a negative prostate biopsy (group 3, n = 22). DNA in plasma preparations were isolated, hybrid-captured, and DNA fragments (200 bp, 1.3, 1.8, and 2.4 kb) were multiplexed
in real-time PCR. A baseline cutoff was determined for individual fragment lengths to establish a DIA score for each patient
sample.
Results: Patients with prostate cancer (86 of 123; 69.9%) were determined to have a positive DIA score of ≥7. The DIA results from
control groups 1, 2, and 3 showed specificities of 90%, 92%, and 68.2%, respectively. Of the patients with negative age-adjusted
prostate-specific antigen (PSA) and prostate cancer, 19 of 30 (63%) had a positive DIA score. The area under the receiver
operating characteristic curve for DIA was 0.788.
Conclusion: While detecting 69.9% of those with prostate cancer, DIA maintained an overall specificity of 68.2% to 92%, a range favorably
comparable to that currently accepted for PSA (60-70%). The variability in specificity between control groups is likely explained
by the established 19% to 30% detection of prostate cancer on subsequent biopsies associated with control group 3. DIA detected
63% of the prostate cancers undetected by currently accepted PSA ranges.</description><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>cell-free DNA</subject><subject>DNA integrity assay (DIA)</subject><subject>DNA, Neoplasm - blood</subject><subject>DNA, Neoplasm - genetics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>plasma, prostate cancer</subject><subject>Predictive Value of Tests</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction - methods</subject><subject>Sensitivity and Specificity</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElP6zAURi30EPNPeE_ePCQWAQ-x47ArYZQQIAaxtBznug1Kk2K7Qv33uLSIJat7F-e7w0HoLyXHlAp1QkmhMpJzdlxVjxmRGaGcbKAdKkSRcSbFn9R_M9toN4Q3QmhOSb6FtqlUZSkJ30Gv53cjfNNHGPs2LvAoBLM4xSP80JkwNdmZCdDgJ-sB-rYf4-dh6LAbPI4TwOcQwcZ26PHg8IMfQjQRcGV6C34fbTrTBThY1z30cnnxXF1nt_dXN9XoNrOCipg1zhbgatu4WqSD6lwWltamZk2h0uHOgrLS1lwo5ggUjRSSKetEXvOy4aThe-hwNXfmh_c5hKinbbDQdaaHYR60VAUrS6F-BVnyl3MhEyhWoE0fBQ9Oz3w7NX6hKdFL9XqpVS-16qReE6mX6lPu33rBvJ5C85Nau07A_zVggjWd80lUG344RThjqkjc0YqbtOPJR-tB2y-lHgIYbyeaMk2FzoUs-SeMtJnF</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>HANLEY, Robert</creator><creator>RIEGER-CHRIST, Kimberly M</creator><creator>CANES, David</creator><creator>EMARA, Norah R</creator><creator>SHUBER, Anthony P</creator><creator>BOYNTON, Kevin A</creator><creator>LIBERTINO, John A</creator><creator>SUMMERHAYES, Ian C</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer</title><author>HANLEY, Robert ; RIEGER-CHRIST, Kimberly M ; CANES, David ; EMARA, Norah R ; SHUBER, Anthony P ; BOYNTON, Kevin A ; LIBERTINO, John A ; SUMMERHAYES, Ian C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-dfc7efbcdfb5960b467c1bab2d78043fce8c6cb3582f0e7d65628cf54b39d30d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>cell-free DNA</topic><topic>DNA integrity assay (DIA)</topic><topic>DNA, Neoplasm - blood</topic><topic>DNA, Neoplasm - genetics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>plasma, prostate cancer</topic><topic>Predictive Value of Tests</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction - methods</topic><topic>Sensitivity and Specificity</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HANLEY, Robert</creatorcontrib><creatorcontrib>RIEGER-CHRIST, Kimberly M</creatorcontrib><creatorcontrib>CANES, David</creatorcontrib><creatorcontrib>EMARA, Norah R</creatorcontrib><creatorcontrib>SHUBER, Anthony P</creatorcontrib><creatorcontrib>BOYNTON, Kevin A</creatorcontrib><creatorcontrib>LIBERTINO, John A</creatorcontrib><creatorcontrib>SUMMERHAYES, Ian C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HANLEY, Robert</au><au>RIEGER-CHRIST, Kimberly M</au><au>CANES, David</au><au>EMARA, Norah R</au><au>SHUBER, Anthony P</au><au>BOYNTON, Kevin A</au><au>LIBERTINO, John A</au><au>SUMMERHAYES, Ian C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>12</volume><issue>15</issue><spage>4569</spage><epage>4574</epage><pages>4569-4574</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: The aim of this study was to evaluate the utility of the DNA integrity assay (DIA) as a plasma-based screening tool for the
detection of prostate cancer.
Experimental Design: Blood samples were collected from patients with biopsy-proven prostate cancer prior to prostatectomy ( n = 123) and processed as two-spin plasma preparations. The three control groups included: males <40 years old with no history
of cancer (group 1, n = 20); cancer-free postprostatectomy patients (group 2, n = 25), and patients with a negative prostate biopsy (group 3, n = 22). DNA in plasma preparations were isolated, hybrid-captured, and DNA fragments (200 bp, 1.3, 1.8, and 2.4 kb) were multiplexed
in real-time PCR. A baseline cutoff was determined for individual fragment lengths to establish a DIA score for each patient
sample.
Results: Patients with prostate cancer (86 of 123; 69.9%) were determined to have a positive DIA score of ≥7. The DIA results from
control groups 1, 2, and 3 showed specificities of 90%, 92%, and 68.2%, respectively. Of the patients with negative age-adjusted
prostate-specific antigen (PSA) and prostate cancer, 19 of 30 (63%) had a positive DIA score. The area under the receiver
operating characteristic curve for DIA was 0.788.
Conclusion: While detecting 69.9% of those with prostate cancer, DIA maintained an overall specificity of 68.2% to 92%, a range favorably
comparable to that currently accepted for PSA (60-70%). The variability in specificity between control groups is likely explained
by the established 19% to 30% detection of prostate cancer on subsequent biopsies associated with control group 3. DIA detected
63% of the prostate cancers undetected by currently accepted PSA ranges.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>16899603</pmid><doi>10.1158/1078-0432.CCR-06-0130</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-08, Vol.12 (15), p.4569-4574 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68729958 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Antineoplastic agents Biological and medical sciences cell-free DNA DNA integrity assay (DIA) DNA, Neoplasm - blood DNA, Neoplasm - genetics Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases Pharmacology. Drug treatments plasma, prostate cancer Predictive Value of Tests Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Reverse Transcriptase Polymerase Chain Reaction - methods Sensitivity and Specificity Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A14%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNA%20Integrity%20Assay:%20A%20Plasma-Based%20Screening%20Tool%20for%20the%20Detection%20of%20Prostate%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=HANLEY,%20Robert&rft.date=2006-08-01&rft.volume=12&rft.issue=15&rft.spage=4569&rft.epage=4574&rft.pages=4569-4574&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-06-0130&rft_dat=%3Cproquest_cross%3E68729958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20134356&rft_id=info:pmid/16899603&rfr_iscdi=true |